These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1066 related articles for article (PubMed ID: 9815731)

  • 1. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
    Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2.
    Satoh M; Seki S; Hashimoto W; Ogasawara K; Kobayashi T; Kumagai K; Matsuno S; Takeda K
    J Immunol; 1996 Nov; 157(9):3886-92. PubMed ID: 8892619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of interleukin-12 receptor beta1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells.
    Wu C; Warrier RR; Wang X; Presky DH; Gately MK
    Eur J Immunol; 1997 Jan; 27(1):147-54. PubMed ID: 9022011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of IL-7 and IL-12 on human T cell activation.
    Mehrotra PT; Grant AJ; Siegel JP
    J Immunol; 1995 May; 154(10):5093-102. PubMed ID: 7730615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
    Naume B; Gately M; Espevik T
    J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of NK-like activity in T cells by IL-2/anti-CD3 is linked to expression of a new antitumour receptor with specificity for acetylated mannose.
    Zollner TM; Zhu HG; Anderer FA
    Anticancer Res; 1993; 13(4):923-30. PubMed ID: 8352560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced lymphokine production and lymphokine receptor expression in multiple antibody-stimulated human CD4+ peripheral blood lymphocytes.
    Conlon KC; Ochoa AC; Kopp WC; Ortaldo JR; Urba WJ; Longo DL; Young HA
    J Immunol; 1992 Nov; 149(10):3278-89. PubMed ID: 1358968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective activation of resting human gamma delta T lymphocytes by interleukin-2.
    Kjeldsen-Kragh J; Quayle AJ; Skålhegg BS; Sioud M; Førre O
    Eur J Immunol; 1993 Sep; 23(9):2092-9. PubMed ID: 8370391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
    Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
    Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-12 activates human gamma delta T cells: synergistic effect of tumor necrosis factor-alpha.
    Ueta C; Kawasumi H; Fujiwara H; Miyagawa T; Kida H; Ohmoto Y; Kishimoto S; Tsuyuguchi I
    Eur J Immunol; 1996 Dec; 26(12):3066-73. PubMed ID: 8977306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
    Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
    Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
    Ortaldo JR; Frey J; Takeshita T; Sugamura K
    Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
    Weil-Hillman G; Voss SD; Fisch P; Schell K; Hank JA; Sosman JA; Sugamura K; Sondel PM
    Cancer Res; 1990 May; 50(9):2683-91. PubMed ID: 1691679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
    Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
    Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th1-mediated intestinal inflammation in Crohn's disease may be induced by activation of lamina propria lymphocytes through synergistic stimulation of interleukin-12 and interleukin-18 without T cell receptor engagement.
    Okazawa A; Kanai T; Watanabe M; Yamazaki M; Inoue N; Ikeda M; Kurimoto M; Ishii H; Hibi T
    Am J Gastroenterol; 2002 Dec; 97(12):3108-17. PubMed ID: 12492197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-gamma/delta+ T lymphocytes. I. Inhibition of the IL-2-dependent proliferation by anti-Kp43 monoclonal antibody.
    Aramburu J; Balboa MA; Ramírez A; Silva A; Acevedo A; Sánchez-Madrid F; De Landázuri MO; López-Botet M
    J Immunol; 1990 Apr; 144(8):3238-47. PubMed ID: 1691231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.